Magazine Archive

Click the thumbnails below to view the Life Sciences IP Review magazines.

LSIPR Spring/Summer 2022

Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape.

LSIPR new recruit Sarah Speight asks lawyers working in the space what this means for patent protection before digging deeper into the issues around plant breeders’ rights and the hot potato that is genetically modified organisms (page 6). Elsewhere in this issue, we look at the rules around induced infringement in the US (page 7) and why, for those alleging it, timing is everything.

And this LSIPR brings you yet more in-depth articles full of future promise, looking at everything from start-ups to fungi.

LSIPR Autumn 2021

This issue examines big pharma's five-step plan, its alternative to the controversial IP waiver. Elsewhere, it analyses the impact of China's latest IP laws, the potentially chilling effect of the ‘essentially derived varieties’ concept protecting plant varieties, and experimental use exemptions in the UK, plus more.

LSIPR Spring/Summer 2021

The Spring/Summer edition of LSIPR includes warnings about patent eligibility for digital healthcare. Focusing on two cases, one involving the growing areas of bioinformatics, our authors explain why having a novel and useful invention may not be enough.

We also look into the Federal Circuit's trend of undermining certain antibody claims, the European Patent Office's new examination guidelines, and where life sciences startups are choosing to file patents.

Meanwhile, heard the one about the Wuhan lab and remdesivir? A curious situation involving COVID-19, Gilead, and China's updated patent laws is explored, offering more questions than answers. Enjoy the issue!